BridgeBio Pharma (NASDAQ:BBIO – Get Rating) and Benitec Biopharma (NASDAQ:BNTC – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, dividends, earnings and risk.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for BridgeBio Pharma and Benitec Biopharma, as provided by MarketBeat.com.
Get BridgeBio Pharma alerts:| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BridgeBio Pharma | 0 | 0 | 5 | 0 | 3.00 |
| Benitec Biopharma | 0 | 0 | 2 | 0 | 3.00 |
BridgeBio Pharma currently has a consensus target price of $23.00, indicating a potential upside of 172.84%. Benitec Biopharma has a consensus target price of $4.00, indicating a potential upside of 1,613.80%. Given Benitec Biopharma's higher probable upside, analysts clearly believe Benitec Biopharma is more favorable than BridgeBio Pharma.
Earnings and Valuation
This table compares BridgeBio Pharma and Benitec Biopharma's revenue, earnings per share and valuation.| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BridgeBio Pharma | $69.72 million | 18.07 | -$562.54 million | ($3.36) | -2.51 |
| Benitec Biopharma | $70,000.00 | 93.30 | -$18.21 million | ($119.48) | 0.00 |
Benitec Biopharma has lower revenue, but higher earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Benitec Biopharma, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares BridgeBio Pharma and Benitec Biopharma's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BridgeBio Pharma | -553.52% | N/A | -67.43% |
| Benitec Biopharma | N/A | -203.69% | -151.61% |
Risk and Volatility
BridgeBio Pharma has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500. Comparatively, Benitec Biopharma has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500.
Institutional and Insider Ownership
96.5% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 69.7% of Benitec Biopharma shares are held by institutional investors. 29.6% of BridgeBio Pharma shares are held by company insiders. Comparatively, 1.6% of Benitec Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
BridgeBio Pharma beats Benitec Biopharma on 7 of the 13 factors compared between the two stocks.
About BridgeBio Pharma
(Get Rating)
BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.
About Benitec Biopharma
(Get Rating)
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.
Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.